Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 231

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Open access
Dahabreh, Issa J., Linardou, Helen, Siannis, Fotios, Fountzilas, George, Murray, Samuel · 2008 · The Oncologist

Abstract

Learning Objectives: After completing this course, the reader will be able to: Summarize the main characteristics and findings of randomized controlled trials evaluating trastuzumab for the adjuvant treatment of early-stage breast cancer.Use combined-effect estimates provided by meta-analysis to appraise the risks and benefits of trastuzumab treatment in the adjuvant setting.Identify the links between basic science and drug development that led to the successful clinical use of trastuzumab, as well as the gaps in the existing evidence base regarding its use in breast cancer treatment. CME This article is available for continuing medical education credit at CME.TheOncologist.com Background.: We performed a systematic review and meta-analysis to compare treatment outcomes for human epidermal growth factor receptor (HER)-2–positive breast cancer patients receiving adjuvant chemotherapy with or without trastuzumab. Methods.: We identified randomized clinical trials comparing adjuvant chemotherapy with or without trastuzumab in patients with resectable breast cancer. Fixed-effects meta-analysis was used to combine data. Results.: Five eligible trials were identified, reporting outcomes on 13,493 women. Fixed-effects analysis showed disease-free survival to be superior for trastuzumab-treated patients (risk ratio [RR], 0.62; 95% confidence interval [CI], 0.56–0.68). Superiority was also observed for patients receiving trastuzumab with respect to mortality (RR, 0.66; 95% CI, 0.57–0.77), locoregional recurrence (RR, 0.58; 95% CI, 0.43–0.77), and distant recurrence (RR, 0.60; 95% CI, 0.52–0.68). Patients receiving trastuzumab with chemotherapy had a higher risk for congestive heart failure (RR, 7.60; 95% CI, 4.07–14.18) and left ventricular ejection fraction decline (RR, 2.09; 95% CI, 1.84–2.37). A higher risk for central nervous system metastasis as the first recurrence event (RR, 1.60; 95% CI, 1.06–2.40) was also noted in patients receiving trastuzumab. Conclusions.: The use of trastuzumab should be considered an integral part of the adjuvant therapy of HER-2–positive breast cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2008-0001

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 231

Metadata

Authors
Dahabreh, I. J., Linardou, H., Siannis, F., Fountzilas, G., & Murray, S.
Venue
The Oncologist
Published
2008-06-01
Volume
13
Issue
6
Pages
620-630
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2129816567
Cited by
231
References
5
FWCI
1.21
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. https://app.cochat.ai/papers/10.1634/theoncologist.2008-0001
The paper
Dahabreh, I. J., Linardou, H., Siannis, F., Fountzilas, G., & Murray, S. (2008). Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. The Oncologist. https://doi.org/10.1634/theoncologist.2008-0001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.